Efficacy of carboplatin-etoposide rechallenge after first-line chemo-immunotherapy in ES-SCLC: an international multicentric analysis.

Autor: Gomez-Randulfe I; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK., Silva Díaz S; Medical Oncology, Complejo Hospitalario Universitario A Coruña, Coruña, Spain., Escriu C; Medical Oncology, The Clatterbridge Cancer Centre, Liverpool, UK., Mohammed S; Oncology Department, Maidstone Hospital, Maidstone, UK., Shah R; Oncology Department, Maidstone Hospital, Maidstone, UK., Benitez Fuentes JD; Clinical Oncology, Velindre Cancer Centre NHS Wales, Cardiff, UK., Cox S; Clinical Oncology, Velindre Cancer Centre NHS Wales, Cardiff, UK., Monaca F; Medical Oncology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., Bria E; Medical Oncology Department, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy., García-Campelo MR; Medical Oncology, Complejo Hospitalario Universitario A Coruña, Coruña, Spain., Crook B; Royal Cornwall Hospital, Truro, UK., Talbot T; Royal Cornwall Hospital, Truro, UK., Leporati R; Oncology Department, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy., Balachandran K; Oncology Department, Chelsea and Westminster Hospital NHS Trust, London, UK., Newsom-Davis T; Oncology Department, Chelsea and Westminster Hospital NHS Trust, London, UK., Hughes S; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK., Cove-Smith L; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK., Taylor P; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK., Blackhall F; Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK.; Division of Cancer Sciences, The University of Manchester, Manchester, UK., Califano R; Department of Medical Oncology, The Christie NHS Foundation Trust, Wilmslow Road, Manchester M20 4BX, UK Division of Cancer Sciences, The University of Manchester, Manchester, UK.

Publikováno v: Therapeutic advances in medical oncology [Ther Adv Med Oncol] 2024 Sep 19; Vol. 16, pp. 17588359241272957. Date of Electronic Publication: 2024 Sep 19 (Print Publication: 2024).

Intracranial Efficacy of Atezolizumab, Bevacizumab, Carboplatin, and Paclitaxel in Real-World Patients with Non-Small-Cell Lung Cancer and EGFR or ALK Alterations.

Autor: Rathbone M; School of Medicine, University of Liverpool, Liverpool L69 3BX, UK., O'Hagan C; School of Medicine, University of Liverpool, Liverpool L69 3BX, UK., Wong H; The Clatterbridge Cancer Centre, Liverpool L7 8YA, UK., Khan A; The Clatterbridge Cancer Centre, Liverpool L7 8YA, UK., Cook T; The Clatterbridge Cancer Centre, Liverpool L7 8YA, UK., Rose S; The Clatterbridge Cancer Centre, Liverpool L7 8YA, UK., Heseltine J; The Clatterbridge Cancer Centre, Liverpool L7 8YA, UK., Escriu C; School of Medicine, University of Liverpool, Liverpool L69 3BX, UK.; The Clatterbridge Cancer Centre, Liverpool L7 8YA, UK.

Publikováno v: Cancers [Cancers (Basel)] 2024 Mar 22; Vol. 16 (7). Date of Electronic Publication: 2024 Mar 22.

A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer

Autor: Warren, A, Massie, C, Watt, K, Luko, K, Orafidiya, F, Selth, L, Mohammed, H, Chohan, B, Menon, S, Baridi, A, Zhao, W, Escriu, C, Pungsrinont, T, D'Santos, C, Yang, X, Taylor, C, Qureshi, A, Zecchini, V, Shaw, G, Dehm, S, Mills, I, Carroll, J, Tilley, W, McEwan, I, Baniahmad, A, Neal, D, Asim, M

Publikováno v: Oncogene
Warren, A Y, Massie, C E, Watt, K, Luko, K, Orafidiya, F, Selth, L A, Mohammed, H, Chohan, B S, Menon, S, Baridi, A, Zhao, W, Escriu, C, Pungsrinont, T, D'Santos, C, Yang, X, Taylor, C, Qureshi, A, Zecchini, V R, Shaw, G L, Dehm, S M, Mills, I G, Carroll, J S, Tilley, W D, McEwan, I J, Baniahmad, A, Neal, D E & Asim, M 2018, ' A reciprocal feedback between the PDZ binding kinase and androgen receptor drives prostate cancer ', Oncogene . https://doi.org/10.1038/s41388-018-0501-z, https://doi.org/10.1038/s41388-018-0501-z

Elucidation of mechanisms underlying the increased androgen receptor (AR) activity and subsequent development of aggressive prostate cancer (PrCa) is pivotal in developing new therapies. Using a systems biology approach, we interrogated the AR-regula

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a402a3b828a556f56075c971e911a047
http://europepmc.org/articles/PMC6514849

MA06.06 A Phase II Trial of Ceralasertib and Durvalumab in Advanced Non-Small Cell Lung Cancer (NSCLC) with and without RAS Mutations: Results of NLMT Arm J

Autor: Middleton, G., Fletcher, P., Savage, J., Mehmi, M., Greystoke, A., Dangoor, A., Cave, J., Escriu, C., Shaw, P., Steele, N., Jain, P., Popat, S., Forster, M., Spicer, J., Coupe, N., Danson, S., Gilligan, D., Muthukumar, D., Price, G., Summers, Y., Toy, E., Billingham, L.

Publikováno v: In Journal of Thoracic Oncology November 2023 18(11) Supplement:S119-S120

1423P Clinical impact of radiological diagnosis of lymphangitic carcinomatosis in patients with extensive non-small cell lung cancer treated with immunotherapy

Autor: Bolina, A., Sallam, M., Ortega Franco, A., Wong, H., Cobben, D., Escriu, C.

Publikováno v: In Annals of Oncology October 2023 34 Supplement 2:S812-S812